← All trials
NCT04904536
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2021
- Primary completion
- Jan 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- May 27, 2021
- Last posted
- Oct 7, 2021
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of New South WalesLead sponsor
- University of New South WalesOverall official - principal investigator
- University of SydneyCollaborator
- Monash UniversityCollaborator
- Monash UniversityCollaborator
- Universidad del DesarrolloCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.